Therapeutic potential of Ishophloroglucin a from Ishige okamurae in androgenic alopecia: inhibition of 5α-reductase activity and activation of the Wnt/β-catenin signaling pathway in human dermal papilla cells
- Authors
- Kim, Wook-Chul; Kim, Hyun-Soo; Kang, Nalae; Heo, Soo-Jin; Lee, Seung-Hong
- Issue Date
- Jan-2026
- Publisher
- 한국응용생명화학회
- Keywords
- Androgenic alopecia; Ishige okamurae; Ishophloroglucin a; Human dermal papilla cell; Wnt/beta-catenin signaling
- Citation
- Applied Biological Chemistry, v.69, no.1
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Applied Biological Chemistry
- Volume
- 69
- Number
- 1
- URI
- https://scholarworks.gnu.ac.kr/handle/sw.gnu/82178
- DOI
- 10.1186/s13765-025-01067-w
- ISSN
- 2468-0834
2468-0842
- Abstract
- Androgenic alopecia (AGA) is a common condition of hair loss, triggered by excessive 5 alpha-dihydrotestosterone (5 alpha-DHT) generated via 5 alpha-reductase activity. This study investigated the anti-alopecia effects of Ishophloroglucin A (IPA), a compound isolated from the brown seaweed Ishige okamurae. Molecular docking analysis revealed that IPA exhibits higher binding affinity to 5 alpha-reductase than finasteride. In human dermal papilla cells (HDPCs), IPA inhibited both 5 alpha-reductase activity and androgen receptor (AR) expression, reduced levels of dickkopf-related protein 1 (DKK1), transforming growth factor beta 1 (TGF-beta 1), and interleukin-6 (IL-6), and activated the Wnt/beta-catenin signaling pathway by promoting glycogen synthase kinase-3 beta (GSK3 beta) phosphorylation and upregulating beta-catenin (beta-catenin) expression. Additionally, IPA increased the expression of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), both of which are associated with hair growth promotion. These findings suggest that IPA is a promising therapeutic candidate for treating AGA.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 해양과학대학 > ETC > Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.